Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Prothena Corporation plc is a biotechnology business based in the US. Prothena Corporation shares (PRTA) are listed on the NASDAQ and all prices are listed in US Dollars. Prothena Corporation employs 82 staff and has a trailing 12-month revenue of around $142.8 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $60.63 |
|---|---|
| 52-week range | $21.06 - $75.00 |
| 50-day moving average | $30.26 |
| 200-day moving average | $33.00 |
| Wall St. target price | $66.38 |
| PE ratio | 19.7347 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.47 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $60.63 from 2022-09-30
| 1 week (2022-09-23) | 97.23% |
|---|---|
| 1 month (2022-09-01) | 120.23% |
| 3 months (2022-07-01) | 117.39% |
| 6 months (2022-04-01) | 55.22% |
| 1 year (2021-10-01) | -14.29% |
|---|---|
| 2 years (2020-10-01) | 488.07% |
| 3 years (2019-10-01) | 681.31% |
| 5 years (2017-09-29) | 64.77 |
Valuing Prothena Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Prothena Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Prothena Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Prothena Corporation shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Prothena Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Prothena Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $142.8 million |
|---|---|
| Gross profit TTM | $118.3 million |
| Return on assets TTM | -0.64% |
| Return on equity TTM | -0.42% |
| Profit margin | -1.03% |
| Book value | $8.70 |
| Market capitalisation | $1.4 billion |
TTM: trailing 12 months
We're not expecting Prothena Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Prothena Corporation's shares have ranged in value from as little as $21.06 up to $75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Prothena Corporation's is 1.3244. This would suggest that Prothena Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.